Enteric coated risedronate 35mg for the treatment of osteoporosis

Description

In this Product Explainer, Endocrinologist Prof Ego Seeman explains the role of enteric coated risedronate 35mg for the treatment of osteoporosis (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Gary Wittert

Prof Gary Wittert

The Peptide Craze – What You Need to Know

Prof Andrew Sindone AM

Prof Andrew Sindone AM

Managing Acute Heart Failure After Discharge: A Practical Guide for GPs

A/Prof Gino Pecoraro OAM

A/Prof Gino Pecoraro OAM

Oral Contraceptives on the PBS – A Practical Guide for GPs

Dr Terri Foran

Dr Terri Foran

The Impact of PFAS & Other Endocrine Disrupting Chemicals on Fertility

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Ego Seeman

expert

Prof Ego Seeman

Endocrinologist; Dept of Medicine and Endocrinology, Austin Health, University of Melbourne; Editor, Progress in Osteoporosis

Date published: 7 November 2023